Genta/French R&D
Executive Summary
Agreement calls for the Centre de Pharmacologie Clinique et d'Evaluation Therapeutiques of Marseilles, France "to conduct clinical trials on up to nine products" being developed by Genta or Genta/Jago, a joint venture with Jagotec A, Genta says in May 6 release. Genta estimates that 68% of the cost of trials could be picked up by the French government, a value of up to $10 mil. The collaboration will focus on dermatologic, Anticode and Geomatrix- based drugs. The first study will be a Phase I trial of Genta's G-301, a topical formulation of methotrexate for severe psoriasis.